N4BP2

Across TCGA pan-cancer cohorts, N4BP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated N4BP2 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher N4BP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated N4BP2 expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where N4BP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.199	0.487	.003	30	view →
HNSC	DFS	Median	All	0.890	0.986	.005	21	view →
LUAD	OS	Quartile	All	0.630	0.937	.017	12	view →
LSCC	OS	Tertile	III,IV	0.473	0.918	.047	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

N4BP2–PDAC (DFS)

Open the PDAC breakdown →